GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » LeMaitre Vascular Inc (NAS:LMAT) » Definitions » Intrinsic Value: Projected FCF

LeMaitre Vascular (LeMaitre Vascular) Intrinsic Value: Projected FCF : $24.15 (As of May. 05, 2024)


View and export this data going back to 2006. Start your Free Trial

What is LeMaitre Vascular Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-05), LeMaitre Vascular's Intrinsic Value: Projected FCF is $24.15. The stock price of LeMaitre Vascular is $74.22. Therefore, LeMaitre Vascular's Price-to-Intrinsic-Value-Projected-FCF of today is 3.1.

The historical rank and industry rank for LeMaitre Vascular's Intrinsic Value: Projected FCF or its related term are showing as below:

LMAT' s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 1.53   Med: 2.35   Max: 4.08
Current: 3.07

During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of LeMaitre Vascular was 4.08. The lowest was 1.53. And the median was 2.35.

LMAT's Price-to-Projected-FCF is ranked worse than
74.21% of 349 companies
in the Medical Devices & Instruments industry
Industry Median: 1.7 vs LMAT: 3.07

LeMaitre Vascular Intrinsic Value: Projected FCF Historical Data

The historical data trend for LeMaitre Vascular's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LeMaitre Vascular Intrinsic Value: Projected FCF Chart

LeMaitre Vascular Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.86 17.24 21.64 21.67 24.15

LeMaitre Vascular Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.67 21.41 22.42 23.29 24.15

Competitive Comparison of LeMaitre Vascular's Intrinsic Value: Projected FCF

For the Medical Instruments & Supplies subindustry, LeMaitre Vascular's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LeMaitre Vascular's Price-to-Projected-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, LeMaitre Vascular's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where LeMaitre Vascular's Price-to-Projected-FCF falls into.



LeMaitre Vascular Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get LeMaitre Vascular's Free Cash Flow(6 year avg) = $23.31.

LeMaitre Vascular's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Dec23)*0.8)/Shares Outstanding (Diluted Average)
=(13.048222848751*23.30816+297.9*0.8)/22.459
=24.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LeMaitre Vascular  (NAS:LMAT) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

LeMaitre Vascular's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=74.22/24.152903774627
=3.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LeMaitre Vascular Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of LeMaitre Vascular's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


LeMaitre Vascular (LeMaitre Vascular) Business Description

Traded in Other Exchanges
Address
63 Second Avenue, Burlington, MA, USA, 01803
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are primarily used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes the largest proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.
Executives
George W Lemaitre director, 10 percent owner, officer: Chairman, President and CEO 342 BUNKER HILL STREET, #2B, CHARLESTOWN MA 02129
Bridget A Ross director C/O HENRY SCHEIN, INC., 135 DURYEA ROAD, MELVILLE NY 11747
John A Roush director C/O GSI GROUP INC., 125 MIDDLESEX TURNPIKE, BEDFORD MA 01730-1409
Lawrence J Jasinski director SOTEIRA INC., 14 TECH CIRCLE, NATICK MA 01760
David B Roberts director, officer: CFO and Director 55 BRADFORD STREET, NEEDHAM MA 02492
Trent G Kamke officer: Senior V. P., Operations 61 WILLOWDEAN AVENUE, WEST ROXBURY MA 02132
Martha Shadan director 9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Pellegrino Joseph P Jr officer: Executive V.P. Finance 68 BEACON STREET, BOSTON MA 02108
Michael H Thomas director P.O. BOX 2207, NOKOMIS FL 34274-2207
Peter R Gebauer officer: President, International OP AM WALDFELD 17, BAD SODEN 2M 65812
Michael T Wijas officer: VP of Sales, The Americas C/O LEMAITRE VASCULAR, INC., 63 SECOND AVENUE, BURLINGTON MA 01803
Lemaitre Cornelia W director, officer: V.P., Human Resources,Director 8 SUNSET ROCK ROAD, ANDOVER MA 01810
Russell D Hays director C/O BIOSOURCE INTERNATIONAL INC, 542 FLYNN RD, CAMARILLO CA 93012
Robert V Linden officer: VP, North American Sales 236 WOODEN BRIDGE ROAD, HOLLAND PA 18966
Thorndike William N Jr director HOUSATONIC PARTNERS, 800 BOYLSTON STREET, SUITE 2220, BOSTON MA 02199

LeMaitre Vascular (LeMaitre Vascular) Headlines

From GuruFocus

LeMaitre to Present at Upcoming Investor Conferences

By Value_Insider Value_Insider 11-22-2022

Should Investors Worry About LeMaitre Vascular Inc's Insider Sells?

By GuruFocus Research GuruFocus Editor 05-20-2023

LeMaitre Q2 2023 Financial Results

By Marketwired 08-01-2023

LeMaitre to Present at Upcoming Investor Conferences

By Value_Insider Value_Insider 11-02-2022

LeMaitre to Distribute Aziyo Biologics' Cardiovascular Patches

By sperokesalga sperokesalga 04-20-2023